Barclays PLC Has $7.97 Million Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Barclays PLC increased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 423,221 shares of the company's stock after purchasing an additional 17,744 shares during the period. Barclays PLC owned 0.92% of Pacira BioSciences worth $7,972,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its holdings in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after buying an additional 513 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after purchasing an additional 918 shares during the period. Sterling Capital Management LLC increased its position in Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares during the last quarter. Caitlin John LLC raised its stake in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares during the period. Finally, Teacher Retirement System of Texas raised its position in shares of Pacira BioSciences by 17.4% in the 4th quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company's stock worth $258,000 after buying an additional 2,034 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded down $0.28 during trading on Friday, hitting $25.72. 466,540 shares of the stock were exchanged, compared to its average volume of 980,809. The stock has a market cap of $1.19 billion, a PE ratio of -12.67 and a beta of 0.71. The stock's fifty day moving average is $24.50 and its 200 day moving average is $21.49. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright upped their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Royal Bank of Canada restated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $26.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.